BrainBaseline Competitors

The brain is central to every aspect of our lives, yet it isn’t monitored with the same consistency and proactivity as other vital signs. As a neuroscience technology company, we believe that better brain health insights lead to better brain health outcomes. That's why we're on a mission to democratize cognitive health by radically simplifying the way it is measured. For more than 20 years, we’ve proudly supported the research needs of biopharmaceutical companies and academic institutions, and the clinical care needs of physicians and individuals around the world. We create easy to use digital tests that provide rapid, reliable, and science-backed results and offer solutions that support the highest fidelity measurements possible. We believe our team members should have flexibility as to how, when, and where they work. We work flexibly to support our global team, who mostly work from home––and offer opportunities for face-to-face collaboration at our offices in New Haven, Melbourne, and London. Our team members also have access to co-working spaces around the world.

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.

Cognitive health starts here. Neurotrack’s rapid digital cognitive screening can identify patients with cognitive impairment in just 3 minutes. This tool enables clinicians—for the first time ever—to screen and monitor cognitive function as they would any other vital sign. We believe it will increase the number of annual cognitive assessments completed, open the door to meaningful early intervention, improve access to new pharmaceutical treatment options, and validate or alleviate patient concerns. By design, it fits easily within a typical primary care annual wellness visit workflow. It scores instantly and objectively, requires no specialized training to administer, and uses culturally-agnostic symbols and numbers to ensure inclusivity and remove barriers to care. In 40 seconds, a medical assistant can set a patient up to take the screening on a tablet independently in an exam room, then upload results to the EMR. Or patients can be sent a link to take the test remotely and walk in ready to discuss results. As a complement to this first-line screening, Neurotrack offers access to patient education and coaching to support a brain-healthy lifestyle. Neurotrack has published 25 peer-reviewed papers and its solutions have been recognized by leading organizations including the Cleveland Clinic and the National Institute on Aging. Working with providers, health systems and employer partners, Neurotrack has enabled more than 170,000 cognitive assessments on its platform. In February 2023, Neurotrack was named winner of the Alzheimer’s Association Pitch Competition, aimed at identifying innovations to increase cognitive assessment and early detection and diagnosis of dementia within primary care settings. In August 2023, we were named to the Norrsken Impact/100, a list of the world's top impact startups. The company has raised a total of $57 million in funding to support and accelerate its go-to-market push with major health systems and providers.